Clinical Trials Browser

Phase 2 × OTHER × Urothelial Carcinoma Bladder × Clear all

NCT05401279 2022-08-18

Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer

Phase 2 Unknown

Urothelial Carcinoma Bladder